165 related articles for article (PubMed ID: 37257766)
1. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
[TBL] [Abstract][Full Text] [Related]
2. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with PD-1 inhibition plus rapamycin and metformin enhances anti-tumor efficacy in triple negative breast cancer.
Tan X; Li Y; Hou Z; Zhang M; Li L; Wei J
Exp Cell Res; 2023 Aug; 429(1):113647. PubMed ID: 37225011
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
6. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
7. The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8
Xia W; Zhang S; Duan H; Wang C; Qian S; Shen H
Med Oncol; 2022 Jan; 39(3):37. PubMed ID: 35059863
[TBL] [Abstract][Full Text] [Related]
8. SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus.
Geng W; Cao M; Dong K; An J; Gao H
Cancer Biol Ther; 2023 Dec; 24(1):2206362. PubMed ID: 37170083
[TBL] [Abstract][Full Text] [Related]
9. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
Song L; Liu S; Zhao S
Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
[TBL] [Abstract][Full Text] [Related]
10. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
11. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
Li C; Qiu S; Jin K; Zheng X; Zhou X; Jin D; Xu B; Jin X
Cancer Lett; 2021 Dec; 523():43-56. PubMed ID: 34601021
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive Effects and Potent Anti-tumor Efficacy of mTOR Inhibitor Everolimus in Breast Tumor-bearing Mice.
Rostamzadeh D; Haghshenas MR; Samadi M; Mojtahedi Z; Babaloo Z; Ghaderi A
Iran J Allergy Asthma Immunol; 2022 Jun; 21(3):287-299. PubMed ID: 35822679
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts.
Euceda LR; Hill DK; Stokke E; Hatem R; El Botty R; Bièche I; Marangoni E; Bathen TF; Moestue SA
J Proteome Res; 2017 May; 16(5):1868-1879. PubMed ID: 28290700
[TBL] [Abstract][Full Text] [Related]
19. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
20. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
